Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study.
Wan-Ju Annabelle LeeShih-Chieh ShaoTzu-Chi LiaoSwu-Jane LinChi-Chun LaiEdward Chia-Cheng LaiPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2022)
Patients treated with aflibercept or ranibizumab for different indications may be associated with varying risk of TAEs. The findings provide evidence to support treatment selection, taking indications and TAE risk into consideration.